Actos (Pioglitazone) Cost in South Dakota: 2026 Prices, Insurance, and Savings

Pioglitazone is a thiazolidinedione (TZD) available as the brand-name Actos or in generic form. Taken as an oral tablet once daily, it carries FDA approval for use alongside diet and exercise to enhance blood sugar control in adults with type 2 diabetes. Because pioglitazone is neither a GLP-1 receptor agonist, insulin, nor controlled substance, these classifications affect its pricing, insurance coverage, and eligibility for telehealth prescription.

Generic pioglitazone is one of the least expensive oral diabetes drugs on the market because it has been off patent for years, and in most of the country a cash-pay 30-day supply runs in the low double digits or less at discount pharmacy programs. Coverage is a separate question from price: some state Medicaid programs exclude thiazolidinediones from their preferred drug list in favor of metformin and sulfonylureas, while most commercial plans place the generic on their lowest cost-sharing tier. Because exact cash prices, insurer tier placement, and a specific state's Medicaid formulary status change over time and were not independently verified for this page, treat any dollar figure below as a general range to confirm at the point of purchase, not a quoted price.

What actually determines your price in South Dakota

Three things drive what a South Dakota patient pays: whether the prescription is for brand Actos or generic pioglitazone, whether it runs through insurance or a cash-discount program, and which specific pharmacy fills it.

Generic pioglitazone is a low-cost, off-patent medication nationally, and South Dakota pharmacies are not an exception. Brand-name Actos carries a materially higher list price than the generic, and the overwhelming majority of prescriptions dispensed use the generic when one is available. Beyond that general pattern, this page does not have a verified, dated South Dakota-specific price survey, so specific dollar figures (a particular chain's discount-list price, a particular independent pharmacy's cash price) should be confirmed directly with the pharmacy or through a discount-card lookup tool (GoodRx, SingleCare, RxSaver) at the time of fill, since these prices move frequently and vary by store even within the same city.

The FDA-approved prescribing information for pioglitazone describes the approved tablet strengths (15 mg, 30 mg, 45 mg); pricing across those strengths is typically similar at the generic level, but that is a pharmacy pricing convention, not a regulatory fact.

Does South Dakota Medicaid cover pioglitazone?

Some state Medicaid programs exclude thiazolidinediones from their preferred drug list because metformin and sulfonylureas are cheaper first-line options and are prioritized in national guideline-based treatment algorithms for type 2 diabetes. Whether South Dakota Medicaid currently excludes pioglitazone, covers it with prior authorization, or covers it outright is a state-specific, date-sensitive formulary fact that this page cannot confirm without a verified copy of South Dakota's current preferred drug list. Readers who rely on South Dakota Medicaid should check the state's current PDL or call their managed care plan before assuming either outcome.

State formulary decisions operate within the federal framework described by the Medicaid Drug Rebate Program, but states retain discretion over preferred status, prior authorization criteria, and step-therapy requirements, and those rules change. If pioglitazone is non-preferred or excluded, a prior authorization request generally needs to document a trial of, or contraindication to, first-line agents such as metformin; typical PA turnaround times vary by state and plan and should be confirmed with the specific Medicaid MCO involved rather than assumed.

How commercial insurance typically treats pioglitazone

Generic drugs that have been off patent for years and cost pennies to a few dollars per tablet at wholesale are commonly placed on a plan's lowest generic cost-sharing tier, and thiazolidinediones like pioglitazone generally fit that pattern industry-wide. Brand-name Actos, by contrast, is more likely to sit on a non-preferred brand tier with a higher copay, since a chemically identical generic is available.

This page cannot confirm current, plan-specific tier placement or copay amounts for any named South Dakota insurer (regional or national) without a verified, dated formulary document, and formularies are revised at least annually. Anyone comparing insurance to a cash-discount card should ask two concrete questions before filling: what is the copay under my specific plan's current formulary, and does a discount card price beat that copay when paid outside insurance. For patients on a high-deductible plan who have not met their deductible, a cash-discount price sometimes costs less than running the claim through insurance, though a cash purchase generally will not count toward the deductible; a pharmacist can confirm which option is cheaper for a specific plan on a specific day.

Verification checklist: stable facts vs. facts you must check locally

Use this before quoting a price or coverage rule from this page or any other source.

Stable, federal or clinical facts (do not change by state or by month):

• Pioglitazone is FDA-approved as an adjunct to diet and exercise for glycemic control in type 2 diabetes; it is not approved as a standalone weight-loss drug.
• The FDA label carries a boxed warning regarding congestive heart failure; pioglitazone should not be initiated in patients with NYHA Class III or IV heart failure, and baseline and periodic liver enzyme (ALT) monitoring is part of the labeled precautions. Verify current label language directly: FDA pioglitazone label.
• Pioglitazone is not a controlled substance, so it does not carry DEA-related telehealth prescribing restrictions.
• 503A compounding pharmacies operate under a uniform federal framework (FD&C Act Section 503A) that permits patient-specific compounded formulations nationwide, subject to state pharmacy board licensure. See the FDA's compounding Q&A and compounding laws and policies page.
• Use of pioglitazone for NASH/MASH is off-label; it is not an FDA-approved indication.

Date-sensitive facts you must verify before relying on them (check the date you read them):

• South Dakota Medicaid's current preferred drug list status for pioglitazone (covered, non-preferred, prior-authorization required, or excluded).
• Any specific commercial insurer's current tier placement and copay for pioglitazone in South Dakota.
• Any named pharmacy chain's or discount program's current cash price for a 30-day supply.
• Whether a manufacturer savings card is currently active and what it excludes (government payers typically cannot use manufacturer copay cards).
• South Dakota's current telehealth prescribing statutes and board rules, since state telehealth law is periodically amended.
• Neighboring states' Medicaid coverage of pioglitazone, which varies by state and changes independently of South Dakota's policy; do not assume any two states match.

Should any figures or coverage information in this article differ from guidance provided by your pharmacy, insurance company, or the South Dakota Department of Social Services (Medicaid) at the point of dispensing, defer to their current determination.

Is compounded pioglitazone an option in South Dakota?

Federal law permits 503A pharmacies to compound patient-specific pioglitazone preparations with a valid prescription, and this framework applies uniformly across states, including South Dakota. There are legitimate clinical reasons a patient might need a compounded version rather than a manufactured tablet: a strength not commercially available, a documented allergy to an inactive ingredient (dye, filler, lactose) in the manufactured product, or an inability to swallow tablets that requires a liquid formulation. Outside those situations, a compounded product is unlikely to offer an advantage over the inexpensive manufactured generic, and compounded drugs are not FDA-approved products, meaning they have not been evaluated for safety, effectiveness, or manufacturing consistency the way the approved generic has.

Any South Dakota compounding pharmacy used should hold a current South Dakota Board of Pharmacy license; readers should confirm licensure and ask what USP compounding standards the pharmacy follows.

Can pioglitazone be prescribed by telehealth in South Dakota?

Because pioglitazone is not a controlled substance, it does not carry the DEA in-person examination requirements that apply to stimulants or opioids, and many states, in general, permit non-controlled prescriptions to be issued after a telehealth evaluation that establishes a valid provider-patient relationship. Whether South Dakota's specific telehealth statutes and medical board rules currently require anything beyond that for a new pioglitazone prescription is a state regulatory detail that should be confirmed with the South Dakota Board of Medical and Osteopathic Examiners or a licensed telehealth provider rather than assumed from this page.

A reasonable telehealth evaluation for pioglitazone should include a recent hemoglobin A1c, baseline liver function testing, and a heart failure risk assessment consistent with the FDA boxed warning, since starting the drug in a patient with significant heart failure is a labeled contraindication-level concern.

Off-label use for fatty liver disease (NASH/MASH)

Pioglitazone has been studied in randomized trials for nonalcoholic steatohepatitis (now often called MASH), including a placebo-controlled trial (commonly referred to as PIVENS) that reported histologic improvement in a meaningful share of pioglitazone-treated patients compared with placebo over roughly two years of treatment. This is trial-level evidence supporting an off-label use, not an FDA-approved indication, and the exact effect sizes reported in that trial should be confirmed against the original published paper rather than repeated from a secondhand summary. A clinician considering pioglitazone for NASH should weigh the cardiovascular and heart-failure precautions above alongside any liver-related benefit.

Cost versus GLP-1 medications: what's actually being compared

Pioglitazone is far less expensive than brand-name GLP-1 receptor agonists (such as semaglutide or tirzepatide) at cash price, and this cost gap is well established directionally even though exact current list prices for those drugs change and are outside the scope of this page. Clinically, pioglitazone can meaningfully lower A1c and does not itself cause hypoglycemia when used alone, and it avoids the gastrointestinal side effects common with GLP-1 agonists. The trade-off is weight: pioglitazone is associated with weight gain (from fluid retention and increased subcutaneous fat) in clinical trials, which runs counter to the weight-loss effect most patients see with GLP-1 agonists. For a patient whose primary goal is weight reduction, pioglitazone's cost advantage does not offset this trade-off; for a patient prioritizing affordable glycemic control who does not need weight loss, it may be a reasonable option to discuss with a prescriber.

A separate large cardiovascular outcomes trial (commonly referred to as PROactive) evaluated pioglitazone against a composite of major cardiovascular events in patients with type 2 diabetes and existing macrovascular disease; the specific effect estimate should be confirmed against the original publication before being cited as a fixed number, since this page did not independently verify it.

Other ways to reduce out-of-pocket cost

Discount cards (GoodRx, SingleCare, RxSaver) and cash-pay online pharmacies commonly beat both list price and, sometimes, insurance copays for inexpensive generics like pioglitazone; whether that holds at a specific South Dakota pharmacy on a specific day should be checked at the point of purchase. Patients receiving care at a 340B-covered health center or hospital may access additional discounts through the HRSA 340B Drug Pricing Program, which applies to qualifying safety-net providers; eligibility depends on where care is received, not on zip code alone. Manufacturer savings cards for brand Actos generally cannot be used with Medicare, Medicaid, or other government insurance, and given the low generic price, a savings card is only relevant to the small number of patients whose prescriber has a specific reason to prescribe the brand rather than the generic.

Evidence boundary: what is established and what is not

Established: pioglitazone's FDA-approved indication for type 2 diabetes, its boxed warning for congestive heart failure, its non-controlled-substance status, and the general federal framework permitting 503A compounding and telehealth prescribing of non-controlled drugs. Established, at a general market level: generic pioglitazone is substantially cheaper than brand Actos and cheaper than brand-name GLP-1 agonists.

Plausible but not confirmed by this page: the specific South Dakota Medicaid coverage decision for pioglitazone in 2026, specific commercial insurer tier placements and copays in South Dakota, specific pharmacy chain cash prices in specific South Dakota cities, and neighboring states' current Medicaid PDL status for the drug. Off-label use in NASH is supported by trial-level evidence but is not an FDA-approved indication, and exact trial statistics should be verified against original publications before being used clinically or in patient counseling.

Not established from the material available here: any claim that pioglitazone is equivalent in overall clinical value to GLP-1 agonists, since the two drug classes differ meaningfully on weight effects, which matters for many patients with type 2 diabetes and obesity.

When to seek care rather than rely on this page

Anyone with symptoms of heart failure (new or worsening shortness of breath, rapid weight gain, leg or ankle swelling) while taking pioglitazone should contact their prescriber promptly or seek urgent evaluation, given the boxed warning. Anyone with signs of liver injury (yellowing skin or eyes, dark urine, unusual fatigue, abdominal pain) should stop and seek medical evaluation. This page does not provide individualized dosing or diagnosis; decisions about starting, stopping, or switching diabetes medications should be made with a licensed prescriber who knows the patient's full history.